Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors
Ostergaard L et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90: 300-305.
Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor
Heiss JD et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996; 98: 1400-1408.
Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: A flow cytometry study
Badie B et al. Dexamethasone-induced abolition of the inflammatory response in an experimental glioma model: a flow cytometry study. J Neurosurg 2000; 93: 634-639.
Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different posttranscriptional mechanisms
Mozo L et al. Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different posttranscriptional mechanisms. J Allergy Clin Immunol 1998; 102: 968-976.
Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene
Benedetti S et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther 1997; 8: 1345-1353.
Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene
Benedetti S et al. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res 1999; 59: 645-652.
Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine
Okada H et al. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 1999; 6: 219-226.
Cytokine gene therapy of gliomas: Induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity
Giezeman-Smits KM et al. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 2000; 60: 2449-2457.
Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo
Wolff JE, Molenkamp G, Hotfilder M, Laterra J. Dexamethasone inhibits glioma-induced formation of capillary like structures in vitro and angiogenesis in vivo. Klin Padiatr 1997; 209: 275-277.
Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells
Machein MR et al. Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 1999; 25: 104-112.
Novel biological functions of interleukin-4: Formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo
Fukushi J et al. Novel biological functions of interleukin-4: formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem Biophys Res Commun 1998; 250: 444-448.
Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma
discussion 493-484
Iwasaki K, Rogers LR, Estes ML, Barna BP. Modulation of proliferation and antigen expression of a cloned human glioblastoma by interleukin-4 alone and in combination with tumor necrosis factor-alpha and/or interferon-gamma. Neurosurgery 1993; 33: 489-493; discussion 493-484.